Teva Pharmaceutical CEO Discusses Q3 Earnings, Growth Strategy, and API Business Sale

Q3 Financial Performance and Growth Drivers

• 📊 Teva Pharmaceuticals reported a strong Q3 with total revenue of $4.48 billion, exceeding consensus estimates.
• 🚀 The company is transitioning from a generics-focused business to a world-class biopharma company, with its innovative branded portfolio showing significant growth.
• 💡 The branded portfolio, relatively new to Teva, grew by 33%, driven by key drugs like Austedo (up 38%), Ajovy (up 24%), and Nucala (up 19%).
• 📈 Even the core generics business saw a 2% increase, contributing to overall revenue and cash flow to fuel the pipeline.

Strategic Focus and Future Pipeline

• 🎯 Teva is committed to its two-year outlook for generics, aiming for a 2% growth rate, which is considered a good return for such a large segment.
• 💊 The company has a robust late-stage innovative pipeline, with new treatments for schizophrenia, asthma, rare diseases, and IBD expected in the coming years.
• 💰 The revenue and cash generated from the generics business are crucial for fueling the pipeline of innovative treatments.

Weight Loss Drug Market and GLP-1 Opportunity

• 📈 Teva sees a significant opportunity in the competitive weight loss drug market, particularly with GLP-1 indications.
• 💊 They have launched their first US generic GLP-1 for weight loss and have partnered for future patent expirations of major GLP-1 drugs.
• ⚠️ While participating in the GLP-1 market, Teva acknowledges the uncertainty around pricing and volume, and other generic products and biosimilars will also drive growth.

Active Pharmaceutical Ingredients (API) Business Sale

• 🔄 Teva is still seeking to divest its active ingredients business, which is the second-largest API supplier globally and not primarily based in China or India.
• 🤝 The company aims to find a partner with whom they can establish long-term service agreements for API supply.
• ⏳ Teva has diminished the urgency for the sale, allowing for a more thoughtful approach to ensure the right deal for shareholders, given their strengthened company position and market changes.
• 🧩 Strategically, divesting the API business aligns with Teva's transformation into a biopharma company.